Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genomic Vision to Extend its Strategic R&D Alliance with Quest Diagnostics

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
Quest Diagnostics will invest in the planned development of a lab-developed test.

Genomic Vision has announced an extension of its strategic alliance agreement with U.S.-based Quest Diagnostics, the world's leading provider of diagnostic information services.

Under the agreement, Quest Diagnostics will invest in the planned development of a lab-developed test for a hereditary genetic disease.

The company will also collaborate with Genomic Vision to automate the testing process and improve turnaround times for tests that employ DNA combing, a technique from Genomic Vision. Additional terms were not disclosed.

"This development is based on the complementary nature of our expertise. The new automated process will help leverage the potential of DNA combing for testing of large populations, which in turn may help improve detection of diseases such as certain cancers and neurological disorders ", stated Aaron Bensimon, CEO of Genomic Vision.

"This development program should make an automated platform available to our customers by the end of 2013, increasing the throughput of our current platform by an order of magnitude", explained Dr. Bensimon.

Genomic Vision and Quest Diagnostics announced a strategic alliance agreement in July 2011 giving Quest exclusive rights in the United States and certain other territories to develop and sell diagnostic tests based on Genomic Vision's molecular combing technology.

Quest Diagnostics (7.4 billion dollars in 2012 revenues with 41,000 employees) has also taken an equity stake in the French biotech company.

Since that time, Quest Diagnostics has adapted the molecular combing technique to a commercial laboratory, streamlined and automated processes and successfully validated an improved molecular combing assay for the genetic disorder facio-scapulo-humeral muscular dystrophy (FSHD). Quest Diagnostics expects to launch the FSHD lab-developed test this summer.

Quest Diagnostics is also exploring market opportunities for a lab-developed test for Lynch Syndrome, which genetically predisposes an individual to colorectal cancer, based on DNA combing.

In 2012, Genomic Vision launched its first test in Europe designed to diagnose facio-scapulo-humeral muscular dystrophy (FSHD), the second most prevalent muscular dystrophy disorder affecting 1 in 10,000 to 1 in 20,000 people.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genomic Vision to extend its strategic R&D alliance with Quest Diagnostic
Under the agreement, Quest Diagnostics will invest in the planned development of a lab-developed test for a hereditary genetic disease.
Tuesday, June 11, 2013
Genomic Vision Receives EUR 473,000 Boost to Technology Development Program
The certification of two of its projects enables the Company to broaden oncology applications and complete technology development.
Tuesday, January 30, 2007
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
BGI Sequences Gingko Tree, Revealing Large, Highly Repetitive Genome
Researchers at BGI have sequenced the more than 10-gigabase ginkgo genome to find a high number of repetitive sequences as well as a number of gene clusters that appear to be involved in defense mechanisms.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!